Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NASDAQ:CRBP NASDAQ:KURA NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$57.51+1.3%$60.17$11.40▼$72.36$1.65B0.72519,810 shs827,833 shsCRBPCorbus Pharmaceuticals$8.26+2.6%$9.55$6.72▼$20.56$149.15M2.57747,740 shs297,769 shsKURAKura Oncology$9.93+3.8%$9.39$5.45▼$12.49$849.57M0.362.02 million shs1.70 million shsURGNUrogen Pharma$33.57+2.3%$26.82$12.73▼$33.79$1.60B1.59601,188 shs847,100 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+1.30%+6.03%-3.78%-7.79%+145.87%CRBPCorbus Pharmaceuticals+2.61%+6.17%-9.73%-3.95%-0.60%KURAKura Oncology+3.76%+12.08%+10.83%+20.22%+63.86%URGNUrogen Pharma+2.32%+13.80%+18.79%+90.52%+125.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$57.51+1.3%$60.17$11.40▼$72.36$1.65B0.72519,810 shs827,833 shsCRBPCorbus Pharmaceuticals$8.26+2.6%$9.55$6.72▼$20.56$149.15M2.57747,740 shs297,769 shsKURAKura Oncology$9.93+3.8%$9.39$5.45▼$12.49$849.57M0.362.02 million shs1.70 million shsURGNUrogen Pharma$33.57+2.3%$26.82$12.73▼$33.79$1.60B1.59601,188 shs847,100 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio+1.30%+6.03%-3.78%-7.79%+145.87%CRBPCorbus Pharmaceuticals+2.61%+6.17%-9.73%-3.95%-0.60%KURAKura Oncology+3.76%+12.08%+10.83%+20.22%+63.86%URGNUrogen Pharma+2.32%+13.80%+18.79%+90.52%+125.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.69Moderate Buy$81.8242.27% UpsideCRBPCorbus Pharmaceuticals 2.75Moderate Buy$41.78405.78% UpsideKURAKura Oncology 2.69Moderate Buy$25.46156.41% UpsideURGNUrogen Pharma 2.86Moderate Buy$39.5017.66% UpsideCurrent Analyst Ratings BreakdownLatest KURA, URGN, CRBP, and ANAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$54.00 ➝ $52.006/15/2026KURAKura Oncology Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/15/2026KURAKura Oncology Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$24.006/10/2026ANABAnaptysBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$95.006/4/2026KURAKura Oncology Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026KURAKura Oncology CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/4/2026KURAKura Oncology Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/3/2026URGNUrogen Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/2/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/2/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/28/2026KURAKura Oncology OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.00(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M7.13N/AN/A$1.34 per share42.92CRBPCorbus PharmaceuticalsN/AN/AN/AN/A$8.40 per shareN/AKURAKura Oncology$67.48M13.06N/AN/A$2.00 per share4.97URGNUrogen Pharma$109.79M14.90N/AN/A($2.25) per share-14.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$1.08N/A17.70N/A-11.53%-1,101.24%-7.75%8/5/2026 (Estimated)CRBPCorbus Pharmaceuticals-$78.54M-$5.82N/AN/AN/AN/A-70.89%-61.78%8/11/2026 (Estimated)KURAKura Oncology-$278.67M-$3.35N/AN/AN/A-411.19%-141.95%-43.28%8/6/2026 (Estimated)URGNUrogen Pharma-$153.49M-$2.75N/A23.98N/A-94.83%N/A-62.85%8/6/2026 (Estimated)Latest KURA, URGN, CRBP, and ANAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ANABAnaptysBio-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26-$1.23+$0.03-$1.23N/AN/A5/12/2026Q1 2026KURAKura Oncology-$0.88-$0.83+$0.05-$0.83$25.97 million$18.27 million5/7/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A7.587.58CRBPCorbus PharmaceuticalsN/A7.927.92KURAKura Oncology0.096.156.14URGNUrogen PharmaN/A4.694.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ACRBPCorbus Pharmaceuticals64.64%KURAKura OncologyN/AURGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%CRBPCorbus Pharmaceuticals3.50%KURAKura Oncology7.60%URGNUrogen Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.10 million19.35 millionOptionableCRBPCorbus Pharmaceuticals4018.53 million17.88 millionOptionableKURAKura Oncology13088.77 million82.03 millionOptionableURGNUrogen Pharma20048.72 million46.38 millionOptionableKURA, URGN, CRBP, and ANAB HeadlinesRecent News About These CompaniesIs UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?June 14, 2026 | fool.comGuggenheim Remains a Buy on Urogen Pharma (URGN)June 10, 2026 | theglobeandmail.comUroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 10, 2026 | seekingalpha.comMark Schoenberg Sells 5,222 Shares of Urogen Pharma (NASDAQ:URGN) StockJune 10, 2026 | insidertrades.comUrogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by BrokeragesJune 9, 2026 | americanbankingnews.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comUroGen settles with Teva over Jelmyto patent disputeJune 3, 2026 | msn.comUroGen, Teva Settle Jelmyto Patent Dispute, License GenericJune 2, 2026 | tipranks.comUroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solutionJune 2, 2026 | globenewswire.comUroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 1, 2026 | globenewswire.comWhat to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock SurgeMay 24, 2026 | aol.comAHow UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) InvestorsMay 23, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN) and CervoMed (CRVO)May 18, 2026 | theglobeandmail.comUroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer TranscriptMay 17, 2026 | seekingalpha.comUroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBCMay 15, 2026 | globenewswire.comUroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION TrialMay 13, 2026 | globenewswire.comURGN Share News TodayMay 12, 2026 | uk.investing.comUrogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?May 11, 2026 | zacks.comAssessing UroGen Pharma (URGN) Valuation After Q1 2026 Earnings Beat And Zusduri Launch MomentumMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKURA, URGN, CRBP, and ANAB Company DescriptionsAnaptysBio NASDAQ:ANAB$57.51 +0.74 (+1.30%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$57.54 +0.02 (+0.04%) As of 06/18/2026 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Corbus Pharmaceuticals NASDAQ:CRBP$8.26 +0.21 (+2.61%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$8.20 -0.06 (-0.79%) As of 06/18/2026 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Kura Oncology NASDAQ:KURA$9.93 +0.36 (+3.76%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$9.76 -0.16 (-1.66%) As of 06/18/2026 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Urogen Pharma NASDAQ:URGN$33.57 +0.76 (+2.32%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$33.64 +0.07 (+0.21%) As of 06/18/2026 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
